Drug intelligence / Profile preview

GB-AOS3

Development stage: Unknown
Lead developer: GlycosBio
Modality: Small Molecules
Administration: Topical

Overview

GB-AOS3 is a clinical-stage therapeutic candidate developed by GlycosBio for the prevention and treatment of dental caries (tooth decay). It is formulated using the company's proprietary Activated Oil System (AOS), a lipid-based delivery platform designed to enhance the stability and biological activity of specific bioactive lipids. GB-AOS3 is intended to target and disrupt the formation of cariogenic biofilms, particularly those involving *Streptococcus mutans*, thereby reducing the production of enamel-eroding acids in the oral cavity. The AOS technology allows for the integration of these antimicrobial lipids into various oral care formats, providing a non-antibiotic approach to managing oral microbiome health and preventing the progression of dental decay.

Brand names: General Clean
Other names: GB-AOS3GB-AOS-3GB-AOS 3

Beyond the preview

Go deeper on GB-AOS3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-AOS3.

Explore the full profile